Scientific Opinion on the substantiation of a health claim related to OptiEFAX™ and maintenance of normal blood HDL-cholesterol concentrations pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 10, Issue 7, 2012, Pages

[No Author Info available]

Author keywords

cholesterol; HDL; health claims; krill oil; OptiEFAX

Indexed keywords

EID: 84958177346     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2012.2803     Document Type: Article

References (3)

1. Bunea R, El Farrah K and Deutsch L, 2004. Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Alternative Medicine Review, 9, 420–428.
2. Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R and Rains TM, 2009. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutrition Research, 29, 609–615.
3. Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vik H and Pedersen JI, 2011. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids, 46, 37–46.